Lord, Abbett & Co’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Lord, Abbett & Co's NRIX Position: Q3 2026 in Review
Lord, Abbett & Co opened a new position in Nurix Therapeutics (NRIX) in Q3 2026: 729,423 shares worth $17.3M. The stake represents 0.05% of the portfolio and ranks #324 among its holdings. This is a return to the name: Lord, Abbett & Co previously reported a position in NRIX as recently as Q4 2024.
Lord, Abbett & Co first reported a position in NRIX in Q3 2024 and has held it in 3 quarters since. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Lord, Abbett & Co held 729,423 shares of Nurix Therapeutics worth $17.3M as of Q3 2026.
- Nurix Therapeutics was a new Lord, Abbett & Co position in Q3 2026.
- Nurix Therapeutics made up 0.05% of Lord, Abbett & Co's portfolio in Q3 2026, its #324 holding.
- Lord, Abbett & Co first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 3 quarters since.
- 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.